Wockhardt Limited (WOCKPHARMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wockhardt Limited (WOCKPHARMA) has a cash flow conversion efficiency ratio of -0.005x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-220.00 Million ≈ $-2.38 Million USD) by net assets (Rs46.57 Billion ≈ $503.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check WOCKPHARMA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Wockhardt Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Wockhardt Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. See WOCKPHARMA book value for net asset value and shareholders' equity analysis.
Wockhardt Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wockhardt Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotus Health Group Co
SHG:600186
|
0.052x |
|
Cosan S.A
SA:CSAN3
|
0.125x |
|
ADEIA CORP
NASDAQ:ADEA
|
0.125x |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
-0.038x |
|
Hefei Chipmore Technology Co. Ltd. A
SHG:688352
|
N/A |
|
Seek Ltd
AU:SEK
|
0.064x |
|
Towne Bank
NASDAQ:TOWN
|
0.040x |
|
Guangzhou Baiyun International Airport Co Ltd
SHG:600004
|
0.048x |
Annual Cash Flow Conversion Efficiency for Wockhardt Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Wockhardt Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Wockhardt Limited market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs46.57 Billion ≈ $503.64 Million |
Rs-220.00 Million ≈ $-2.38 Million |
-0.005x | -107.90% |
| 2024-03-31 | Rs36.62 Billion ≈ $396.03 Million |
Rs2.19 Billion ≈ $23.68 Million |
0.060x | +43.14% |
| 2023-03-31 | Rs36.62 Billion ≈ $396.03 Million |
Rs1.53 Billion ≈ $16.55 Million |
0.042x | -57.49% |
| 2022-03-31 | Rs42.02 Billion ≈ $454.43 Million |
Rs4.13 Billion ≈ $44.66 Million |
0.098x | +228.63% |
| 2021-03-31 | Rs37.60 Billion ≈ $406.66 Million |
Rs-2.87 Billion ≈ $-31.07 Million |
-0.076x | -136.00% |
| 2020-03-31 | Rs30.57 Billion ≈ $330.65 Million |
Rs6.49 Billion ≈ $70.18 Million |
0.212x | +247.89% |
| 2019-03-31 | Rs30.05 Billion ≈ $324.94 Million |
Rs1.83 Billion ≈ $19.83 Million |
0.061x | +185.08% |
| 2018-03-31 | Rs31.98 Billion ≈ $345.84 Million |
Rs684.40 Million ≈ $7.40 Million |
0.021x | +129.53% |
| 2017-03-31 | Rs37.19 Billion ≈ $402.16 Million |
Rs-2.69 Billion ≈ $-29.14 Million |
-0.072x | -539.46% |
| 2016-03-31 | Rs43.43 Billion ≈ $469.66 Million |
Rs716.10 Million ≈ $7.74 Million |
0.016x | -82.07% |
| 2015-03-31 | Rs38.59 Billion ≈ $417.37 Million |
Rs3.55 Billion ≈ $38.39 Million |
0.092x | -76.84% |
| 2014-03-31 | Rs37.18 Billion ≈ $402.05 Million |
Rs14.76 Billion ≈ $159.66 Million |
0.397x | -29.92% |
| 2013-03-31 | Rs27.04 Billion ≈ $292.45 Million |
Rs15.32 Billion ≈ $165.72 Million |
0.567x | -29.62% |
| 2012-03-31 | Rs14.71 Billion ≈ $159.09 Million |
Rs11.84 Billion ≈ $128.08 Million |
0.805x | +41.30% |
| 2011-03-31 | Rs11.26 Billion ≈ $121.82 Million |
Rs6.42 Billion ≈ $69.41 Million |
0.570x | +347.19% |
| 2010-03-31 | Rs8.35 Billion ≈ $90.33 Million |
Rs-1.93 Billion ≈ $-20.82 Million |
-0.231x | -288.42% |
| 2009-03-31 | Rs10.18 Billion ≈ $110.06 Million |
Rs1.25 Billion ≈ $13.46 Million |
0.122x | -58.70% |
| 2008-03-31 | Rs12.74 Billion ≈ $137.73 Million |
Rs3.77 Billion ≈ $40.79 Million |
0.296x | +67.51% |
| 2007-03-31 | Rs10.66 Billion ≈ $115.32 Million |
Rs1.89 Billion ≈ $20.39 Million |
0.177x | -29.49% |
| 2006-03-31 | Rs8.16 Billion ≈ $88.26 Million |
Rs2.05 Billion ≈ $22.13 Million |
0.251x | -22.04% |
| 2005-03-31 | Rs6.17 Billion ≈ $66.68 Million |
Rs1.98 Billion ≈ $21.45 Million |
0.322x | -- |
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more